赛轮轮胎（601058）公告，2025年4月11日至2025年6月20日，公司实际控制人袁仲雪之一致行动人瑞元 鼎实因集中竞价交易方式增持3282.15万股公司股份，持有公司股份比例从24.00%变动至25.00%，权益 变动触及1%刻度。2024年11月25日至2025年6月20日，瑞元鼎实增持9296.23万股，持股比例从12.79% 变动至15.62%，权益变动触及5%刻度。本次权益变动未导致公司控股股东、实际控制人及第一大股东 发生变化。 ...

证券代码：603668 证券简称：天马科技 公告编号：2025-044 福建天马科技集团股份有限公司 关于控股股东、实际控制人、部分董监高及核心管理人员 增持公司股份计划实施完毕暨增持结果的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 已披露增持计划情况：福建天马科技集团股份有限公司（以下简称"公 司"）控股股东、实际控制人、部分董监高及核心管理人员（以下统称"增持主 体"）拟于 2024 年 8 月 27 日起 12 个月内以自有资金或自筹资金通过上海证券交 易所集中竞价交易系统增持公司股份，拟累计增持金额不低于 2,500 万元（人民 币，下同）且不超过 5,000 万元。 行动人福建天马投资发展有限公司（以下简称"天马投资"）取得了中国农业银 行股份有限公司福清市支行出具的《贷款承诺函》。陈庆堂先生对原增持计划进 行了调整，增加天马投资为增持主体，增持金额相应调整为"不低于 4,650 万元 且不超过 9,300 万元（含此前已增持金额）"。 ? 增持计划的实施结果：自增持计划公布以 ...

● 本次权益变动系上海锦江国际酒店股份有限公司（以下简称"公司"）控 股股东上海锦江资本有限公司（以下简称"锦江资本"）一致行动人锦江国际酒 店集团（香港）投资管理有限公司（以下简称"锦江香港"）实施增持计划导致 持有公司股份比例增加所致。本次权益变动属于增持，不触及要约收购，不会导 致公司控股股东及实际控制人发生变化。 证券代码：600754/900934 证券简称：锦江酒店/锦江B股 公告编号：2025-028 上海锦江国际酒店股份有限公司 关于控股股东一致行动人 增持公司 B 股股份达到 1%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次权益变动后，信息披露义务人锦江资本及其一致行动人锦江香港合计 持有公司股份比例从 45.05%增加至 46.05%。 动人增持公司 B 股股份及后续增持计划的公告》（公告编号：2025-002）。公司 控股股东锦江资本一致行动人锦江香港通过上海证券交易所允许的方式（包括但 不限于集中竞价交易、大宗交易等）增持公司 B 股股份，增持 B 股股份数不低 ...

证券代码：002001 证券简称：新和成 公告编号：2025-033 浙江新和成股份有限公司 公司董事、董事会秘书、副总裁、财务总监石观群先生保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 积极践行"质量回报双提升"行动方案，提振投资者信心，维护市场稳定。 浙江新和成股份有限公司（以下简称"公司"）收到公司董事、董事会秘书、 副总裁、财务总监石观群先生的通知，获悉石观群先生于 2025 年 6 月 17 日通过 二级市场竞价交易方式增持公司股份 200,000 股，占公司总股本的 0.0065%。现 将本次增持股份结果公告如下： 一、增持主体的基本情况 披露义务。 特此公告。 浙江新和成股份有限公司董事会 份 200,000 股，占公司总股本的 0.0065%。 持有公司股份 10,677,838 股，占公司总股本比例为 0.35%。 二、其他说明 和国证券法》《深圳证券交易所上市公司自律监管指引第 10 号——股份变动管 理》等相关法律法规及规范性文件的规定。 个月内不存在减持公司股份的情形。 ...

Summary of Key Points Core Viewpoint - The announcement details the completion of a share buyback plan by a significant shareholder of China Electronics Technology Group Corporation (CETC), reflecting confidence in the company's future prospects and value recognition [1][4]. Group 1: Buyback Plan Details - The buyback plan was announced with a total investment amount ranging from RMB 250 million to RMB 500 million, aiming to acquire up to 2% of the company's total share capital within 12 months [1][2]. - The buyback was executed through the Shanghai Stock Exchange, utilizing methods such as centralized bidding and block trading [1][2]. Group 2: Implementation Results - As of the announcement date, the shareholder, CETC Investment Holdings Co., Ltd., had acquired a total of 20,277,573 shares, representing 1.71% of the company's total share capital, with a total expenditure of approximately RMB 251.96 million [3][4]. - Following the completion of the buyback plan, the total shares held by the shareholder and its concerted parties increased to 489,106,053 shares, accounting for 41.31% of the total share capital [3][4]. Group 3: Legal Compliance - The buyback actions were confirmed to comply with relevant laws and regulations, including the Securities Law and the Management Measures for Acquisitions [4]. - A legal opinion was issued confirming that the buyback plan adhered to all applicable legal requirements [3][4].

证券代码：000597 证券简称：东北制药 公告编号：2025-047 东北制药集团股份有限公司关于控股股东一致行动人 增持计划实施完成的公告 公司控股股东一致行动人江西方大钢铁集团有限公司保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 方大集团实业有限公司（简称"方大集团"）一致行动人江西方大钢铁集团有限 公司（以下简称"方大钢铁/增持主体"）计划自 2024 年 12 月 11 日起 6 个月内 增持公司股份，计划增持金额不少于人民币 7,500 万元,不超过人民币 15,000 万 元。 圳证券交易所以集中竞价交易方式合计增持公司股份 14,629,900 股，占公司总 股本比例的 1.0237%，合计增持金额为 7,500.4222 万元（不含交易费用），本次 增持计划已实施完成。 （二）增持计划披露前，增持主体已持有公司股份数量及比例：公司控股股 东为方大集团，直接持有公司 329,068,713 股股份，占公司总股本的 23.03%，方 大钢铁直接持有公司 443,231,442 股 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][13]. Core Insights - The controlling shareholder, Juzi Holding, plans to increase its stake in the company by at least HKD 200 million within 3-6 months, reflecting strong confidence in the company's future [2][3]. - The company aims to enhance its brand, expand distribution channels, and strengthen regulatory approvals, focusing on product development and marketing efforts [4]. - The projected earnings per share (EPS) for 2025-2027 are estimated at CNY 2.40, CNY 2.93, and CNY 3.54, with corresponding price-to-earnings (PE) ratios of 23, 19, and 16 [5][11]. Summary by Sections Event Commentary - Juzi Holding announced a plan to increase its shareholding, indicating confidence in the company's prospects [2]. Operational Analysis - Juzi Holding currently holds approximately 54.26% of the company's shares and plans to acquire an additional 3.268 million shares, representing about 0.3% of the total share capital [3]. - The company will focus on increasing R&D investment and enhancing its product offerings, particularly in three categories of medical devices [4]. Future Outlook - The company plans to strengthen its marketing for key brands and develop new brands to support growth in its skincare business [4]. - The product matrix, including medical devices and skincare lines, is expected to continue driving growth [5]. Financial Forecasts - Revenue is projected to grow from CNY 3,524 million in 2023 to CNY 10,921 million by 2027, with a compound annual growth rate (CAGR) of approximately 23.95% [11]. - Net profit is expected to increase from CNY 1,452 million in 2023 to CNY 3,790 million by 2027, reflecting a strong growth trajectory [11].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688222 证券简称：成都先导 公告编号：2025-018 重要内容提示： ● 本次增持主体宁波聚智先导生物科技合伙企业（有限合伙）（以下简称"聚智先导"）为成都先导药物 开发股份有限公司（以下简称"公司"或"成都先导"）持股5%以上股东、员工持股平台，与公司控股股 东、实际控制人JIN LI（李进）为一致行动人关系。截至本公告披露日，聚智先导持有公司38,651,163 股股份，占总股本的比例为9.65%，JIN LI（李进）持有公司81,876,948股股份，占总股本的比例为 20.43%，聚智先导与JIN LI（李进）合计持有公司120,528,111股股份，占总股本的比例为30.08%。 ● 成都先导于今日收到公司控股股东、实际控制人JIN LI（李进）的一致行动人聚智先导的通知，基于 对公司未来持续稳定发展的信心以及对公司股票长期投资价值的认可，聚智先导拟自本公告披露之日起 12个月内，通过包括但不限于集中竞价、大宗交易等上海证券交易所交易系统允许的方式增持公司股 份，合计增持金额不低于人民币2,500万元（含）且不高于人民币5,000万 ...

Group 1 - Daqian Ecology announced that shareholder Xinhua Publishing Group plans to reduce its stake by up to 4,071,600 shares, representing no more than 3% of the total share capital [2] - Vice President Wang Zheng'an intends to reduce his holdings by up to 410,798 shares, which is no more than 25% of his total holdings and approximately 0.3027% of the company's total share capital [2] - The reduction period is set from June 16, 2025, to September 15, 2025 [2] Group 2 - Sanofi's stock has experienced a significant increase, with a cumulative rise of over 30% in two consecutive trading days and over 100% in four consecutive trading days, indicating abnormal trading fluctuations [2] - The company has entered into a collaboration with Pfizer for the 707 project, which involves a dual-specific antibody product targeting PD-1 and VEGF, with uncertain sales milestone payments and royalties based on market conditions [2] - The actual receipt of sales milestone payments and royalties is subject to uncertainties related to drug demand, market competition, and sales channels [2] Group 3 - Xinhua Insurance announced a commitment to invest 10 billion yuan in the second phase of the Honghu Fund, which has a total fund size of 20 billion yuan [3] - The establishment of the fund is pending regulatory procedures, and the implementation timeline may vary [3] - Sany Heavy Industry has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange, with the application materials being subject to updates [3] Group 4 - Laisentongling's stock has seen a 33.17% increase over three consecutive trading days, with a turnover rate of 40.49%, indicating potential speculative trading [3] - The company confirmed that its main operations remain stable, with no significant changes in daily operations or major contracts signed recently [3] - The production costs and sales conditions are reported to be normal [3]

中国石化（600028）公告，2025年5月14日，中国石化集团通过其全资附属公司在香港联合交易所首次 增持了公司3.02亿股H股股份，约占公司已发行总股份的0.25%，增持金额为港币12.32亿元。增持后， 中国石化集团持有公司13.45亿股H股股份。中国石化集团及其一致行动人后续将按照增持计划继续择机 增持公司股份。 ...